Factors associated with early-onset androgenetic alopecia: A scoping review
- PMID: 38451966
- PMCID: PMC10919688
- DOI: 10.1371/journal.pone.0299212
Factors associated with early-onset androgenetic alopecia: A scoping review
Abstract
Background: Early-onset androgenetic alopecia (AGA) has been associated with various chronic conditions, including metabolic syndrome (MetS). Gaining a deep understanding of early-onset AGA may enable earlier intervention in individuals at high risks. This scoping review aims to explore the risk factors and etiology, associated conditions, and adverse effects on wellbeing in early-onset AGA.
Methods: Electronic literature searches were conducted in MEDLINE, EMBASE and CENTRIAL. Eligible studies included case-control, cohort, cross-sectional, and meta-analysis studies. Selected studies needed to clearly define early-onset AGA cases or include only cases starting before the age of 40 and compare them with appropriate controls. The exclusion criteria comprised editorials, commentaries, case series, and non-systematic reviews, among others. Data extraction involved collecting study characteristics, methodologies, main outcomes, and findings. Descriptive tables were used to summarize key information and relevant variables when necessary.
Results: Among the 65 eligible articles, 67.69% were case-control studies and 78.46% evaluated only male patients. "Early-onset" was defined as cases developing before the age of 30 years in 43.08% of the studies. The Hamilton-Norwood scale was the most frequently used method for evaluating the severity of alopecia in men (69.23%). Reported risk factors for early-onset AGA included a family history of AGA, cigarette smoking, unhealthy dietary habits, and a high body mass index. Early-onset AGA may also be associated with hormonal profiles, 5α-reductase enzyme activity, androgen receptor genes, and some susceptibility loci. Comorbidities investigated included MetS, cardiovascular disease, insulin resistance, dyslipidemia, and Parkinson's disease. Men with early-onset AGA may have reduced treatment efficacy with drug like rosuvastatin, metformin or lisinopril for dyslipidemia, prediabetes, or hypertension. Additionally, young men with AGA tended to suffer from psychological issues such as anxiety and low self-esteem compared to those without hair loss.
Conclusion: Early-onset AGA is a complex condition with various risk factors and etiology, associated comorbidities, and potential implications for treatment response and psychological health.
Copyright: © 2024 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Clinical and metabolic characteristics of males with early-onset androgenetic alopecia.Indian J Dermatol Venereol Leprol. 2023 Jul-Aug;89(4):530-535. doi: 10.25259/IJDVL_949_2021. Indian J Dermatol Venereol Leprol. 2023. PMID: 36688892
-
Hyperuricemia is associated with androgenetic alopecia in men: A cross-sectional case-control study.J Cosmet Dermatol. 2020 Nov;19(11):3122-3126. doi: 10.1111/jocd.13401. Epub 2020 Apr 12. J Cosmet Dermatol. 2020. PMID: 32281237
-
The comparison of metabolic syndrome parameters, trichoscopic and trichoscan characteristics in androgenetic alopecia (AGA) and early-onset androgenetic alopecia (early-onset AGA).Arch Dermatol Res. 2024 Aug 29;316(8):581. doi: 10.1007/s00403-024-03297-2. Arch Dermatol Res. 2024. PMID: 39207572
-
Health-Related Quality of Life, Depression, and Self-esteem in Patients With Androgenetic Alopecia: A Systematic Review and Meta-analysis.JAMA Dermatol. 2021 Aug 1;157(8):963-970. doi: 10.1001/jamadermatol.2021.2196. JAMA Dermatol. 2021. PMID: 34232264 Free PMC article.
-
Androgenetic alopecia: an evidence-based treatment update.Am J Clin Dermatol. 2014 Jul;15(3):217-30. doi: 10.1007/s40257-014-0077-5. Am J Clin Dermatol. 2014. PMID: 24848508 Review.
Cited by
-
Hair Growth-Promoting Effect of Hydrangea serrata (Thunb.) Ser. Extract and Its Active Component Hydrangenol: In Vitro and In Vivo Study.Int J Mol Sci. 2024 Sep 26;25(19):10370. doi: 10.3390/ijms251910370. Int J Mol Sci. 2024. PMID: 39408700 Free PMC article.
-
Effectiveness of Autologous Platelet-Rich Plasma for Androgenetic Alopecia: A Double-Center, Non-Controlled, Randomized Clinical Study in Vietnam.Clin Cosmet Investig Dermatol. 2025 Jul 2;18:1645-1656. doi: 10.2147/CCID.S528663. eCollection 2025. Clin Cosmet Investig Dermatol. 2025. PMID: 40620897 Free PMC article.
-
Using the follicular unit extraction technique in treatment of male androgenetic alopecia.BMC Surg. 2024 Nov 15;24(1):358. doi: 10.1186/s12893-024-02655-1. BMC Surg. 2024. PMID: 39543552 Free PMC article.
-
Immune and Non-immune Interactions in the Pathogenesis of Androgenetic Alopecia.Clin Rev Allergy Immunol. 2025 Mar 1;68(1):22. doi: 10.1007/s12016-025-09034-5. Clin Rev Allergy Immunol. 2025. PMID: 40024940 Review.
-
Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024.PLoS One. 2025 Mar 24;20(3):e0309849. doi: 10.1371/journal.pone.0309849. eCollection 2025. PLoS One. 2025. PMID: 40127098 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous